Dozens of guidelines and algorithms are available from a range of authoritative sources to guide selection of psychopharmacology.
Drug Benefit Trends
Health care reform is the topic of every conversation, it seems, and many of these conversations are quite impassioned.
In early November, the FDA announced the launch of the Safe Use Initiative, a program to protect patients from injury and death caused by improper use of over-the-counter and prescription medications.
Only 25% of adults in the United States aged 50 to 64 years receive recommended preventive health services, including influenza vaccination, cholesterol screening, and breast and cervical cancer screening.
SSRIs and related antidepressants are great drugs for the treatment of depression, anxiety, premenstrual disorders, and other conditions. However, sexual dysfunction is very common and affects 30% to 70% of patients,1 or 36% to 43% of patients depending on the particular medications and the study protocol.2 Men are somewhat more likely than women to have difficulty, especially with the desire phase of sexual function. However, it is clear that patients of both sexes may have either phase-specific or global sexual dysfunction while taking antidepressants.
Huskamp and associates recently reported that in the year following the implementation of Part D, many patients dually eligible for Medicaid and Medicare benefits had difficulty gaining access to psychiatric medications.
The Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) was held in Cape Town, South Africa, from July 19 to 22, 2009. More than 5500 delegates from more than 100 countries attended this annual event.
While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacological therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease.
While the facts support the claim from the Centers for Medicare & Medicaid Services (CMS) that beneficiaries have “robust” choices in the sign-up period for 2010 Part D drug coverage plans that begins in November, the number of options available have continued to decline. At the peak in 2007, 1875 stand-alone Medicare drug plans were offered; this year, the number had shrunk to 1659, and the total for next year will be 1510.
We assessed the association between pharmacy cost-containment policy actions by states’ Medicaid programs and access to prescription drug and medical care, controlling for nonpharmacy cost-containment policy actions and socio-environmental differences among states.